Hepatitis C
📧 Sign up to get email alerts when something new happens for Hepatitis C.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2015-10-09Clinical Trial Update: Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials) [Phase 3]
This document reports the completion of a Phase III trial evaluating a quadruple regimen of asunaprevir, daclatasvir, pegylated interferon, …
-
CLINICAL_TRIALS trial_result · 2015-10-09Clinical Trial Update: Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3 [Phase 3]
Phase 3 safety and efficacy trial comparing pegylated interferon lambda with and without daclatasvir against pegylated interferon alfa plus …
-
CLINICAL_TRIALS trial_result · 2015-10-09Clinical Trial Update: UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis [Phase 3]
Phase 3 UNITY 2 evaluates a fixed-dose DCV+ASV+BMS-791325 regimen (DCV 3DAA) with or without RBV for 12 weeks in chronic hepatitis C genotyp…
-
CLINICAL_TRIALS trial_result · 2015-10-09Clinical Trial Update: Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin [Phase 2]
Phase 2 safety study evaluating pegylated interferon lambda in combination with one or two direct-acting antivirals plus ribavirin for hepat…
-
CLINICAL_TRIALS trial_result · 2015-10-09Clinical Trial Update: Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy [Phase 3]
Phase 3 trial evaluating the efficacy and safety of peginterferon lambda-1a plus ribavirin plus daclatasvir in Hepatitis C genotype 1b patie…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2015-10-09Clinical Trial Update: Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin [Phase 2]
Phase 2 safety study evaluating pegylated interferon lambda-1a in combination with one or two direct-acting antiviral agents plus ribavirin …
-
CLINICAL_TRIALS trial_result · 2015-10-09Clinical Trial Update: A Phase 3 Study in Combination With BMS-790052 and BMS-650032 in Japanese Hepatitis C Virus (HCV) Patients [Phase 3]
Phase 3 trial evaluating BMS-790052 in combination with BMS-650032 in Japanese patients with hepatitis C has completed.
-
CLINICAL_TRIALS trial_result · 2015-10-09Clinical Trial Update: Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives) [Phase 3]
A Phase III study named Hallmark DUAL evaluated the combination of asunaprevir and daclatasvir for Hepatitis C, with the trial status showin…
-
CLINICAL_TRIALS trial_result · 2015-10-09Clinical Trial Update: A Single Ascending Dose Study of BMS-791325 in HCV Infected Subjects [Phase 1, Phase 2]
This document notes the completion of a single ascending dose study of BMS-791325 in subjects with chronic hepatitis C in Phase 1/2.
-
CLINICAL_TRIALS trial_result · 2015-10-09Clinical Trial Update: Ph IIA Study (SOC +/- NS5B) [Phase 2]
Phase IIa study evaluating SOC with or without an NS5B inhibitor for hepatitis C has completed.
-
CLINICAL_TRIALS trial_result · 2015-10-06Clinical Trial Update: Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063) [Phase 2, Phase 3]
Three-year follow-up results from a trial comparing boceprevir and narlaprevir in chronic hepatitis C were reported after termination.
-
CLINICAL_TRIALS trial_result · 2015-10-05Clinical Trial Update: Quantification of Side Effects During Hepatitis C Therapy
The document provides quantified data on the side effects observed during hepatitis C therapy in a completed clinical trial led by Medical U…
-
CLINICAL_TRIALS research · 2015-10-02Clinical Trial Update: Vertical Transmission of Hepatitis C Virus
This clinical trial update concerns vertical transmission of Hepatitis C virus; the condition is Hepatitis C and the current status of the t…
-
CLINICAL_TRIALS trial_result · 2015-09-30Clinical Trial Update: Evaluating the Role of Immune Responses in the Emergence of Protease Inhibitor Mutations
This completed University of Cincinnati trial studied how immune responses may influence the emergence of mutations in protease inhibitors f…
-
CLINICAL_TRIALS research · 2015-09-30Clinical Trial Update: Prevention of Graft Reinfection After Liver Transplantation With Anti HCV Monoclonal Antibodies Identified in Chronically Infected Patients or in Patients With Resolved Hepatitis C
The document outlines a clinical trial investigating whether anti-HCV monoclonal antibodies can prevent graft reinfection after liver transp…
-
CLINICAL_TRIALS trial_result · 2015-09-28Clinical Trial Update: Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin in Cirrhotic Subjects With Chronic Genotype 1 HCV Infection [Phase 2]
Phase 2 trial update evaluating sofobuvir/ledipasvir with or without ribavirin in cirrhotic patients with chronic genotype 1 hepatitis C vir…
-
CLINICAL_TRIALS withdrawal · 2015-09-28Clinical Trial Update: Impact of an Antibiotic (Rifaximin) on Liver Scarring in HIV-Infected Patients With Liver Disease [Phase 4]
A Phase 4 clinical trial evaluating rifaximin for liver scarring in HIV-infected individuals with liver disease has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2015-09-25Clinical Trial Update: Efficacy and Safety Study of PEG-IFN-SA and Ribavirin to Treat Chronic Hepatitis C [Phase 3]
Phase 3 clinical trial evaluating PEG-IFN-SA plus ribavirin for chronic hepatitis C has completed; no efficacy or safety results are describ…
-
CLINICAL_TRIALS trial_result · 2015-09-23Clinical Trial Update: A Pilot Study of the Grapefruit Flavonoid Naringenin for HCV Infection [Phase 1]
A Phase 1 pilot study evaluating the grapefruit flavonoid naringenin for hepatitis C virus infection has completed.
-
CLINICAL_TRIALS withdrawal · 2015-09-23Clinical Trial Update: Boceprevir in End Stage Renal Disease (ESRD) [NA]
A Columbia University-sponsored clinical trial evaluating boceprevir for hepatitis C in patients with end-stage renal disease has been withd…
-
CLINICAL_TRIALS trial_result · 2015-09-21Clinical Trial Update: Triple-Therapy in Patients With HCV Genotype 3 Who Previously Failed Treatment [Phase 3]
A Phase 3 clinical trial update reports results for triple-therapy in patients with Hepatitis C genotype 3 who previously failed treatment.
-
CLINICAL_TRIALS trial_result · 2015-09-18Clinical Trial Update: Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2) [Phase 3]
Phase 3 STARTverso 2 trial evaluated faldaprevir in combination with pegylated interferon-alfa and ribavirin for treatment-naïve genotype 1 …
-
CLINICAL_TRIALS trial_result · 2015-09-18Clinical Trial Update: Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 1) [Phase 3]
This Phase 3 trial evaluates faldaprevir in combination with pegylated interferon-alpha and ribavirin in treatment-naïve genotype 1 hepatiti…
-
CLINICAL_TRIALS trial_result · 2015-09-18Clinical Trial Update: UNITY 3: A Japanese Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 in Subjects With Genotype 1 Chronic Hepatitis C [Phase 3]
Phase 3 Japanese UNITY 3 trial evaluating daclatasvir/asunaprevir/BMS-791325 in genotype 1 chronic hepatitis C has completed.
-
CLINICAL_TRIALS trial_result · 2015-09-17Clinical Trial Update: Safety, Antiviral Activity and PK of MRD of BI 201335 in Chronic Hepatitis C Patients Both Treatment Naive and -Experienced [Phase 1]
Phase 1 clinical trial update on safety, antiviral activity, and pharmacokinetics of BI 201335 in treatment-naïve and experienced chronic he…